Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 1:46 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2449–2472 of 9,549 matching trials from the live ClinicalTrials.gov search.

Filters: Birmingham, Alabama Clear all

Conditions: Dry Eye
Interventions: Miebo; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 7
States / cities: Birmingham, Alabama • Petaluma, California • Pittsburg, Kansas + 4 more

Conditions: Caries, Salivary Function, Tooth Sensitivity
Interventions: Resin infiltration, Mock treatment; Device · Other
Lead sponsor: DMG Dental Material Gesellschaft mbH; Industry
Eligibility: 19 Years and older
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Heart Failure, Tachycardia, Ventricular
Interventions: St. Jude Medical Optisure Lead; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 1,735 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 46
States / cities: Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 42 more

Conditions: Cervical Cancer
Interventions: Pembrolizumab, Sacituzumab Tirumotecan, Bevacizumab, Paclitaxel, Cisplatin, Carboplatin, Rescue Medications; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 1,023 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 34
States / cities: Birmingham, Alabama • Anchorage, Alaska • Irvine, California + 29 more

Conditions: Small Cell Lung Carcinoma
Interventions: Pembrolizumab/Vibostolimab Co-Formulation, Saline placebo, Etoposide, Cisplatin, Atezolizumab, Carboplatin; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 11
States / cities: Mobile, Alabama • Los Angeles, California • Boca Raton, Florida + 7 more

Conditions: Stroke, Thromboses, Intracranial, Aneurysm, Brain
Interventions: Stroke/Thrombectomy/Aneurysm-specific surgical procedures; Procedure
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 1 Year to 120 Years
Enrollment: 40,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2055
U.S. locations: 54
States / cities: Birmingham, Alabama • Loma Linda, California • Santa Barbara, California + 48 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Erlotinib, PF-02341066; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 16
States / cities: Birmingham, Alabama • Orange, California • Fort Lauderdale, Florida + 6 more

Conditions: Pediatric Obesity, Executive Function
Interventions: Web Based Treatment; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 8 Years to 14 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Depressive Disorder, Major
Interventions: Rapastinel, Placebo-matching Rapastinel; Drug
Lead sponsor: Naurex, Inc, an affiliate of Allergan plc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 137
States / cities: Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 112 more

Conditions: Posttraumatic Stress Disorder (PTSD)
Interventions: Methylphenidate, Placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama • Seattle, Washington

Conditions: Androgenetic Alopecia (AGA), Androgenetic Alopecia, AGA, Female Androgenetic Alopecia, Hair Loss
Interventions: VDPHL01 QD, Placebo, VDPHL01 BID; Drug
Lead sponsor: Veradermics, Inc.; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 552 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 71
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fort Smith, Arkansas + 65 more

Conditions: Hypertension
Interventions: Renal Denervation (Vessix), Renal Angiography; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 12
States / cities: Birmingham, Alabama • Los Angeles, California • Miami Beach, Florida + 8 more

Conditions: Measles-Mumps-Rubella
Interventions: Priorix, M-M-R II, Kinrix, ProQuad; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 4 Years to 6 Years
Enrollment: 4,011 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 50
States / cities: Birmingham, Alabama • Tucson, Arizona • Benton, Arkansas + 44 more

Conditions: Type 2 Diabetes
Interventions: KRP-104, Placebo; Drug
Lead sponsor: ActivX Biosciences, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 403 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 17
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 14 more

Conditions: Heart Failure
Interventions: Chronicle Implantable Hemodynamic Monitor (IHM) System, Chronicle Implantable Cardioverter Defibrillator (ICD); Device
Lead sponsor: Medtronic Cardiac Rhythm and Heart Failure; Industry
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 19
States / cities: Birmingham, Alabama • Springfield, Illinois • Fort Wayne, Indiana + 16 more

Conditions: SARS-CoV-2
Interventions: mRNA-1273, Placebo; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 30,415 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 100
States / cities: Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 79 more

Conditions: Sickle Cell Disease
Interventions: ITU512, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years to 55 Years
Enrollment: 161 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2030
U.S. locations: 9
States / cities: Birmingham, Alabama • Miami, Florida • Boston, Massachusetts + 6 more

Conditions: Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis
Interventions: Exebacase, Placebo; Drug
Lead sponsor: ContraFect; Industry
Eligibility: 12 Years and older
Enrollment: 259 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 55
States / cities: Birmingham, Alabama • Orange, California • Sacramento, California + 47 more

Conditions: Covid19, AKI, CKD, ESRD, Transplant;Failure,Kidney
Interventions: Not listed
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 5
States / cities: Birmingham, Alabama • San Diego, California • Aurora, Colorado + 2 more

Conditions: Pediatric Migraine
Interventions: Rimegepant/BHV3000, Matching placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 2,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 169
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Tempe, Arizona + 107 more

Conditions: Menstrual Migraine
Interventions: Diary; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Systemic Lupus Erythematosus
Interventions: P-CD19CD20-ALLO1 Cells, Cyclophosphamide, Fludarabine, Rimiducid; Biological · Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 2
States / cities: Birmingham, Alabama • Iowa City, Iowa

Conditions: Cystic Fibrosis
Interventions: QR-010; Drug
Lead sponsor: ProQR Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 3
States / cities: Birmingham, Alabama • Denver, Colorado • Cincinnati, Ohio

Conditions: Ovarian Cancer
Interventions: Standard postpartum tubal ligation, Complete Salpingectomy; Procedure
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 25 Years and older · Female only
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Birmingham, Alabama

Search by objective public record fields.

A Study to Evaluate Early Treatment Outcomes With Miebo™ in Subjects With Dry Eye Disease

Lesion Progression After Icon Treatment in Young Adults

Optisure Lead Post Approval Study

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)

Stroke Thrombectomy and Aneurysm Registry

Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer

Virtual Health Focused Acceptance-Based Program for Parents and Youth

A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder

Methylphenidate for the Treatment of PTSD With Associated Neurocognitive Complaints

Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)

Renal Denervation Using the Vessix Renal Denervation System for the Treatment of Hypertension (REDUCE HTN:REINFORCE)

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age

Safety and Efficacy of Once-Daily KRP-104 in Type 2 Diabetics With Inadequate Glycemic Control on Metformin Alone

Extension Phase of the Chronicle® Offers Management to Patients With Advanced Signs & Symptoms of Heart Failure Study

A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19

A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease

Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase

Global Assessment of Acute and Chronic Kidney Disease Incidence and Outcomes in Patients With COVID-19 Infection

Randomized Study in Children and Adolescents With Migraine: Acute Treatment

An Investigation of the Safety and Utility of Treximet in the Treatment of Menstrual Migraine

A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE)

Exploratory Study to Evaluate QR-010 in Subjects With Cystic Fibrosis ΔF508 CFTR Mutation

Salpingectomy at Cesarean Delivery for Ovarian Cancer Reduction (SCORE)